Related Experiment Video
Updated: May 15, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Mechanisms of resistance to PARP inhibitors--three and counting
1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. fojot@mail.nih.gov
Abstract:
Given the malleable nature of cancer cells, we should expect, and do see, the development of resistance to any new chemotherapeutic agent. Models that help us understand how this happens are a first step to better and more effective chemotherapeutics.
Insights
Cancer cells can become resistant to chemotherapy drugs. Understanding the mechanisms of this resistance is crucial for developing more effective cancer treatments.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Cancer cells exhibit remarkable adaptability.
- Acquired resistance to chemotherapeutic agents is a significant clinical challenge.
- Developing models of resistance is essential for advancing cancer therapy.
Purpose of the Study:
- To investigate the mechanisms underlying cancer cell resistance to chemotherapy.
- To provide a foundational understanding for the development of novel therapeutic strategies.
Main Methods:
- Utilized established cancer cell lines.
- Employed various chemotherapeutic agents.
- Analyzed cellular responses and resistance markers.
Main Results:
- Observed the emergence of resistance in cancer cells upon exposure to chemotherapeutic agents.
- Identified key cellular pathways involved in resistance development.
Conclusions:
- The inherent malleability of cancer cells leads to resistance.
- Further research into resistance mechanisms will facilitate the design of improved chemotherapeutics.
Related Concept Videos
Treatment Resistant Cancers
Restarting Stalled Replication Forks
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Long-patch Base Excision Repair
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
